CPP is a recognizable disorder which, with knowledge, skill and experience, can be managed effectively. The webinar series will inform pediatricians and pediatric endocrinologists how to recognise patients with CPP, and how to identify CPP amongst the wide variations of pubertal development (Bräuner, 2020). Once identified, does the patient with CPP need urgent therapy or a more conservative approach of careful observation? Key aspects of the child with rapidly advancing CPP will be clearly explained and demonstrated. The timing and initiation of GnRHa therapy will be discussed, with presentation of evidence comparing 6-monthly with 3-monthly and monthly administration. The three webinars will be live-streamed, with opportunities for the audience to ask questions and to interact with the Chair and presenters. After each live-stream, a recording of the webinar will be posted online and will be available globally as a free, open-access resource on the MedEA e-learning platform for up to a year after launch.
After attending the live webinars participants will be able to:
Pediatricians, endocrinologists and clinicians involved in growth management.
The official language of this live educational activity will be English. Simultaneous translation into Spanish will be provided.
The Key components in the management of Central Precocious Puberty (CPP) will be submitted for CME accreditation from the European Accreditation Council for Continuing Medical Education (EACCME), the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) and for Continuing Professional Development (CPD) credits.
Key components in the management of Central Precocious Puberty (CPP)
14.00–14.05 Pre-webinar survey - Participants
14.05–14.13 Introduction and aim of webinar - Chair: M.O. Savage (UK)
14.13–14.38 Awareness of CPP within the range of variations of growth and puberty in pediatric endocrine practice - Presenter: Sasha Howard (UK)
14.38–14.50 Panel discussion - Chair/Presenter/Participants
14.50–14.55 Post-webinar survey - Participants
14.55–15.00 Closing remarks - Chair: M.O. Savage (UK)
14.00–14.05 Pre-webinar survey - Participants
14.05–14.13 Introduction and aim of webinar - Chair: M.O. Savage (UK)
14.143–14.38 Early identification of CPP patients requiring GnRH analogue therapy - Presenter: Anders Juul (Denmark)
14.38–14.50 Panel discussion - Chair/Presenter/Participants
14.50–14.55 Post-webinar survey - Participants
14.55–15.00 Closing remarks - Chair: M.O. Savage (UK)
17.00–17.05 Pre-webinar survey - Participants
17.05–17.13 Introduction and aim of webinar - Chair: M.O. Savage (UK)
17.13–17.38 Choice and initiation of GnRHa therapy for CPP with emphasis on long-acting administration - Presenter: Karen Klein (USA)
17.38–17.50 Panel discussion - Chair/Presenter/Participants
17.50–17.55 Post-webinar survey - Participants
17.55–18.00 Closing remarks - Chair: M.O. Savage (UK)
to register for the webinar series
Download Save the Date & Scientific Program